Calycia Biosciences

Calycia Biosciences is a French biotechnology company focused on discovering and developing first-in-class small molecule therapeutics that target the secretory pathway stress response in cancer. The company's approach leverages the vulnerability of cancer cells to proteostatic stress, specifically within the endoplasmic reticulum, to trigger selective cell death. By inhibiting the adaptive mechanisms that allow tumors to survive harsh microenvironments, Calycia aims to provide new treatment options for patients with hard-to-treat solid tumors. The company was founded on pioneering research from the Institut Curie and is supported by leading European life science investors.